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Development of a controlled-release anti-parkinsonian nanodelivery system using 
levodopa as the active agent. 
 
ABSTRACT 
A new layered organic-inorganic nanocomposite material with an anti-parkinsonian active 
compound, L-3-(3,4-dihydroxyphenyl) alanine (levodopa), intercalated into the inorganic 
interlayers of a Zn/Al-layered double hydroxide (LDH) was synthesized using a direct 
coprecipitation method. The resulting nanocomposite was composed of the organic moiety, 
levodopa, sandwiched between Zn/Al-LDH inorganic interlayers. The basal spacing of the 
resulting nano-composite was 10.9 Å. The estimated loading of levodopa in the 
nanocomposite was approximately 16% (w/w). A Fourier transform infrared study showed 
that the absorption bands of the nanocomposite were characteristic of both levodopa and 
Zn/Al-LDH, which further confirmed intercalation, and that the intercalated organic moiety 
in the nanocomposite was more thermally stable than free levodopa. The resulting 
nanocomposite showed sustained-release properties, so can be used in a controlled-release 
formulation. Cytotoxicity analysis using an MTT assay also showed increased cell viability 
of 3T3 cells exposed to the newly synthesized nanocomposite compared with those exposed 
to pure levodopa after 72 hours of exposure. 
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